Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer

N. Y. Hsu, H. C. Ho, K. C. Chow, T. Y. Lin, C. S. Shih, L. S. Wang, C. M. Tsai

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

By using mRNA differential display to examine specimens of non-small cell lung cancer (NSCLC), we have identified overexpression of dihydrodiol dehydrogenase (DDH) that was not detected in the corresponding normal lung tissue. Normally DDH is associated with catalysis of polycyclic aromatic hydrocarbons (PAHs) in the liver; in NSCLC cells, DDH expression would implicate an association with disease progression. In this study we investigated the prognostic significance of DDH expression in patients with NSCLC. By using immunohistochemistry, we measured DDH expression in 381 patients with NSCLC. The relationship between DDH expression and clinicopathological parameters (age, gender, smoking history, mitotic index, histological type, stage, cell differentiation, and lymphovascular invasion) was analyzed by X2 analysis. Survival curves were plotted with the method of Kaplan-Meier, and statistical difference of survivals between different groups was compared by a log-rank test. Our results showed that DDH overexpression could be detected in 317 (83.2%) of 381 pathological sections and in 77.9% (60 of 77) of metastatic lymph nodes. Expression of DDH was confirmed by immunoblotting. Compared with patients with DDH overexpression in tumors, patients with low DDH expression had significantly lower incidence of early tumor recurrence and distant organ metastasis (46.7 versus 29.7%; P = 0.045). Interestingly, survival was also significantly better in patients with low DDH expression than in those with DDH overexpression (P = 0.0017). Using univariate analysis, we correlated three important factors, DDH overexpression, tumor stages, and gender, with poor prognosis for NSCLC patients. Nevertheless, biological function and involvement of DDH in the disease progression of NSCLC require additional studies.

Original languageEnglish
Pages (from-to)2727-2731
Number of pages5
JournalCancer Research
Volume61
Issue number6
Publication statusPublished - Mar 15 2001
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase
Survival
Disease Progression
Neoplasms
Mitotic Index
Polycyclic Aromatic Hydrocarbons
Gene Expression Profiling
Catalysis
Immunoblotting
Cell Differentiation
Lymph Nodes
Smoking
History
Immunohistochemistry
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hsu, N. Y., Ho, H. C., Chow, K. C., Lin, T. Y., Shih, C. S., Wang, L. S., & Tsai, C. M. (2001). Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Research, 61(6), 2727-2731.

Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. / Hsu, N. Y.; Ho, H. C.; Chow, K. C.; Lin, T. Y.; Shih, C. S.; Wang, L. S.; Tsai, C. M.

In: Cancer Research, Vol. 61, No. 6, 15.03.2001, p. 2727-2731.

Research output: Contribution to journalArticle

Hsu, NY, Ho, HC, Chow, KC, Lin, TY, Shih, CS, Wang, LS & Tsai, CM 2001, 'Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer', Cancer Research, vol. 61, no. 6, pp. 2727-2731.
Hsu NY, Ho HC, Chow KC, Lin TY, Shih CS, Wang LS et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Research. 2001 Mar 15;61(6):2727-2731.
Hsu, N. Y. ; Ho, H. C. ; Chow, K. C. ; Lin, T. Y. ; Shih, C. S. ; Wang, L. S. ; Tsai, C. M. / Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. In: Cancer Research. 2001 ; Vol. 61, No. 6. pp. 2727-2731.
@article{391a9b2684dc4bb5985de911bb5e5b55,
title = "Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer",
abstract = "By using mRNA differential display to examine specimens of non-small cell lung cancer (NSCLC), we have identified overexpression of dihydrodiol dehydrogenase (DDH) that was not detected in the corresponding normal lung tissue. Normally DDH is associated with catalysis of polycyclic aromatic hydrocarbons (PAHs) in the liver; in NSCLC cells, DDH expression would implicate an association with disease progression. In this study we investigated the prognostic significance of DDH expression in patients with NSCLC. By using immunohistochemistry, we measured DDH expression in 381 patients with NSCLC. The relationship between DDH expression and clinicopathological parameters (age, gender, smoking history, mitotic index, histological type, stage, cell differentiation, and lymphovascular invasion) was analyzed by X2 analysis. Survival curves were plotted with the method of Kaplan-Meier, and statistical difference of survivals between different groups was compared by a log-rank test. Our results showed that DDH overexpression could be detected in 317 (83.2{\%}) of 381 pathological sections and in 77.9{\%} (60 of 77) of metastatic lymph nodes. Expression of DDH was confirmed by immunoblotting. Compared with patients with DDH overexpression in tumors, patients with low DDH expression had significantly lower incidence of early tumor recurrence and distant organ metastasis (46.7 versus 29.7{\%}; P = 0.045). Interestingly, survival was also significantly better in patients with low DDH expression than in those with DDH overexpression (P = 0.0017). Using univariate analysis, we correlated three important factors, DDH overexpression, tumor stages, and gender, with poor prognosis for NSCLC patients. Nevertheless, biological function and involvement of DDH in the disease progression of NSCLC require additional studies.",
author = "Hsu, {N. Y.} and Ho, {H. C.} and Chow, {K. C.} and Lin, {T. Y.} and Shih, {C. S.} and Wang, {L. S.} and Tsai, {C. M.}",
year = "2001",
month = "3",
day = "15",
language = "English",
volume = "61",
pages = "2727--2731",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer

AU - Hsu, N. Y.

AU - Ho, H. C.

AU - Chow, K. C.

AU - Lin, T. Y.

AU - Shih, C. S.

AU - Wang, L. S.

AU - Tsai, C. M.

PY - 2001/3/15

Y1 - 2001/3/15

N2 - By using mRNA differential display to examine specimens of non-small cell lung cancer (NSCLC), we have identified overexpression of dihydrodiol dehydrogenase (DDH) that was not detected in the corresponding normal lung tissue. Normally DDH is associated with catalysis of polycyclic aromatic hydrocarbons (PAHs) in the liver; in NSCLC cells, DDH expression would implicate an association with disease progression. In this study we investigated the prognostic significance of DDH expression in patients with NSCLC. By using immunohistochemistry, we measured DDH expression in 381 patients with NSCLC. The relationship between DDH expression and clinicopathological parameters (age, gender, smoking history, mitotic index, histological type, stage, cell differentiation, and lymphovascular invasion) was analyzed by X2 analysis. Survival curves were plotted with the method of Kaplan-Meier, and statistical difference of survivals between different groups was compared by a log-rank test. Our results showed that DDH overexpression could be detected in 317 (83.2%) of 381 pathological sections and in 77.9% (60 of 77) of metastatic lymph nodes. Expression of DDH was confirmed by immunoblotting. Compared with patients with DDH overexpression in tumors, patients with low DDH expression had significantly lower incidence of early tumor recurrence and distant organ metastasis (46.7 versus 29.7%; P = 0.045). Interestingly, survival was also significantly better in patients with low DDH expression than in those with DDH overexpression (P = 0.0017). Using univariate analysis, we correlated three important factors, DDH overexpression, tumor stages, and gender, with poor prognosis for NSCLC patients. Nevertheless, biological function and involvement of DDH in the disease progression of NSCLC require additional studies.

AB - By using mRNA differential display to examine specimens of non-small cell lung cancer (NSCLC), we have identified overexpression of dihydrodiol dehydrogenase (DDH) that was not detected in the corresponding normal lung tissue. Normally DDH is associated with catalysis of polycyclic aromatic hydrocarbons (PAHs) in the liver; in NSCLC cells, DDH expression would implicate an association with disease progression. In this study we investigated the prognostic significance of DDH expression in patients with NSCLC. By using immunohistochemistry, we measured DDH expression in 381 patients with NSCLC. The relationship between DDH expression and clinicopathological parameters (age, gender, smoking history, mitotic index, histological type, stage, cell differentiation, and lymphovascular invasion) was analyzed by X2 analysis. Survival curves were plotted with the method of Kaplan-Meier, and statistical difference of survivals between different groups was compared by a log-rank test. Our results showed that DDH overexpression could be detected in 317 (83.2%) of 381 pathological sections and in 77.9% (60 of 77) of metastatic lymph nodes. Expression of DDH was confirmed by immunoblotting. Compared with patients with DDH overexpression in tumors, patients with low DDH expression had significantly lower incidence of early tumor recurrence and distant organ metastasis (46.7 versus 29.7%; P = 0.045). Interestingly, survival was also significantly better in patients with low DDH expression than in those with DDH overexpression (P = 0.0017). Using univariate analysis, we correlated three important factors, DDH overexpression, tumor stages, and gender, with poor prognosis for NSCLC patients. Nevertheless, biological function and involvement of DDH in the disease progression of NSCLC require additional studies.

UR - http://www.scopus.com/inward/record.url?scp=0035866794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035866794&partnerID=8YFLogxK

M3 - Article

C2 - 11289154

AN - SCOPUS:0035866794

VL - 61

SP - 2727

EP - 2731

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -